Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

StatusNot Yet Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 7 months later Jun 1, 2031 → Jan 1, 2032
See other at-risk trials from University of Miami

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jun 1, 2031 to Jan 1, 2032 Show 5 more changesShow less
    • Lead sponsor: Peter Hosein, MD to University of Miami
    • Start date: Jun 1, 2026 to Jan 1, 2027
    • Eligibility criteria expanded, about 53 words
    • Secondary endpoints: details revised at 2 of 2 entries
    • Collaborators: 1 to 2
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of this research study is to see the effects (good or bad) of Lorigerlimab on patients with pancreatic adenocarcinoma (PDAC) and homologous recombination deficiency (HRD).
Trial Details
NCT Number NCT07565155
Lead Sponsor University of Miami
Collaborators: MacroGenics, United States Department of Defense
Conditions
(from sponsor)		 Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov